Global Amyotrophic Lateral Sclerosis Drugs Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI05245081

Publication Date:

May 24, 2024

Pages:

113

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig鈥檚 disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5鈥�10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis Drugs market size is projected to grow from US$ 293.5 million in 2023 to US$ 346.1 million in 2030; it is expected to grow at a CAGR of 2.4% from 2024 to 2030.
The 鈥淎myotrophic Lateral Sclerosis Drugs Industry Forecast鈥� looks at past sales and reviews total world Amyotrophic Lateral Sclerosis Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis Drugs sales for 2024 through 2030. With Amyotrophic Lateral Sclerosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis Drugs industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Amyotrophic Lateral Sclerosis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
Riluzole
Edaravone (Radicava)
CoQ10
Butylphthalide
Others
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Mitsubishi Tanabe Pharma
Mylan
Apotex
Glemark Generics
Sun Pharma
Covis Pharma
Lunan Pharma
CSPC Pharmaceutical
Ascend Laboratories
EISAI

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis Drugs Market Size 2019-2030
2.1.2 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Amyotrophic Lateral Sclerosis Drugs Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 CoQ10
2.2.4 Butylphthalide
2.2.5 Others
2.3 Amyotrophic Lateral Sclerosis Drugs Market Size by Type
2.3.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Type (2019-2024)
2.4 Amyotrophic Lateral Sclerosis Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Amyotrophic Lateral Sclerosis Drugs Market Size by Application
2.5.1 Amyotrophic Lateral Sclerosis Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Application (2019-2024)
3 Amyotrophic Lateral Sclerosis Drugs Market Size by Player
3.1 Amyotrophic Lateral Sclerosis Drugs Market Size Market Share by Players
3.1.1 Global Amyotrophic Lateral Sclerosis Drugs Revenue by Players (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Amyotrophic Lateral Sclerosis Drugs by Regions
4.1 Amyotrophic Lateral Sclerosis Drugs Market Size by Regions (2019-2024)
4.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.4 Europe Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Country (2019-2024)
5.2 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
5.3 Americas Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Region (2019-2024)
6.2 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
6.3 APAC Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis Drugs by Country (2019-2024)
7.2 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
7.3 Europe Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs by Region (2019-2024)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.1 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast
10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast
10.2 Americas Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.2.4 Brazil Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3 APAC Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.3.1 China Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.2 Japan Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.3 Korea Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.4 Southeast Asia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.5 India Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.3.6 Australia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4 Europe Amyotrophic Lateral Sclerosis Drugs Forecast by Country (2025-2030)
10.4.1 Germany Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.2 France Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.3 UK Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.4 Italy Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.4.5 Russia Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5 Middle East & Africa Amyotrophic Lateral Sclerosis Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.2 South Africa Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.3 Israel Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.4 Turkey Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.5.5 GCC Countries Amyotrophic Lateral Sclerosis Drugs Market Forecast
10.6 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Type (2025-2030)
10.7 Global Amyotrophic Lateral Sclerosis Drugs Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Offered
11.1.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Mitsubishi Tanabe Pharma
11.2.1 Mitsubishi Tanabe Pharma Company Information
11.2.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.2.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Mitsubishi Tanabe Pharma Main Business Overview
11.2.5 Mitsubishi Tanabe Pharma Latest Developments
11.3 Mylan
11.3.1 Mylan Company Information
11.3.2 Mylan Amyotrophic Lateral Sclerosis Drugs Product Offered
11.3.3 Mylan Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Mylan Main Business Overview
11.3.5 Mylan Latest Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Amyotrophic Lateral Sclerosis Drugs Product Offered
11.4.3 Apotex Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Apotex Main Business Overview
11.4.5 Apotex Latest Developments
11.5 Glemark Generics
11.5.1 Glemark Generics Company Information
11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Offered
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Glemark Generics Main Business Overview
11.5.5 Glemark Generics Latest Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Company Information
11.6.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.6.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Sun Pharma Main Business Overview
11.6.5 Sun Pharma Latest Developments
11.7 Covis Pharma
11.7.1 Covis Pharma Company Information
11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Covis Pharma Main Business Overview
11.7.5 Covis Pharma Latest Developments
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Information
11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Offered
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Lunan Pharma Main Business Overview
11.8.5 Lunan Pharma Latest Developments
11.9 CSPC Pharmaceutical
11.9.1 CSPC Pharmaceutical Company Information
11.9.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Offered
11.9.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 CSPC Pharmaceutical Main Business Overview
11.9.5 CSPC Pharmaceutical Latest Developments
11.10 Ascend Laboratories
11.10.1 Ascend Laboratories Company Information
11.10.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Offered
11.10.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Ascend Laboratories Main Business Overview
11.10.5 Ascend Laboratories Latest Developments
11.11 EISAI
11.11.1 EISAI Company Information
11.11.2 EISAI Amyotrophic Lateral Sclerosis Drugs Product Offered
11.11.3 EISAI Amyotrophic Lateral Sclerosis Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 EISAI Main Business Overview
11.11.5 EISAI Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂